Drug intelligence / Profile preview

Zeloglin

Development stage: Unknown
Lead developer: Almirall
Modality: Small Molecules
Administration: Topical

Overview

**Zeloglin** is a topical skin cream developed by Polichem S.A. (part of Poli Group, acquired by Almirall in 2015) specifically formulated for the relief of signs and symptoms of mild to moderate rosacea, including flushing, erythema (redness), itching, and burning, as well as mild to moderate acne. It contains azeloglycine (likely azelaic acid derivative) combined with hydroxypropyl-chitosan (HPCH), tocopherol acetate, and UV filters, providing moisturizing, lenitive (soothing), and sebo-regulative properties to manage inflammatory skin conditions. The product is notified in 30 countries and licensed out in 24, with commercialization in Europe, Asia, and other regions as part of Almirall's dermatology portfolio focused on underserved skin disorders.

Brand names: Zeloglin
Other names: Zelorose

Beyond the preview

Go deeper on Zeloglin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zeloglin.

Explore the full profile